HRP20221414T1 - Antifungalni agensi sa pojačanom aktivnošću kod kiselog ph - Google Patents

Antifungalni agensi sa pojačanom aktivnošću kod kiselog ph Download PDF

Info

Publication number
HRP20221414T1
HRP20221414T1 HRP20221414TT HRP20221414T HRP20221414T1 HR P20221414 T1 HRP20221414 T1 HR P20221414T1 HR P20221414T T HRP20221414T T HR P20221414TT HR P20221414 T HRP20221414 T HR P20221414T HR P20221414 T1 HRP20221414 T1 HR P20221414T1
Authority
HR
Croatia
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
iia
formula
Prior art date
Application number
HRP20221414TT
Other languages
English (en)
Croatian (hr)
Inventor
David A. ANGULO GONZALEZ
Original Assignee
Scynexis, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=63209698&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20221414(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Scynexis, Inc. filed Critical Scynexis, Inc.
Publication of HRP20221414T1 publication Critical patent/HRP20221414T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Reproductive Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Dermatology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HRP20221414TT 2017-08-04 2018-07-31 Antifungalni agensi sa pojačanom aktivnošću kod kiselog ph HRP20221414T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762541370P 2017-08-04 2017-08-04
PCT/US2018/044619 WO2019028034A1 (en) 2017-08-04 2018-07-31 Antifungal agents with enhanced activity in acidic ph
EP18755632.9A EP3661503B1 (en) 2017-08-04 2018-07-31 Antifungal agents with enhanced activity in acidic ph

Publications (1)

Publication Number Publication Date
HRP20221414T1 true HRP20221414T1 (hr) 2023-01-20

Family

ID=63209698

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20221414TT HRP20221414T1 (hr) 2017-08-04 2018-07-31 Antifungalni agensi sa pojačanom aktivnošću kod kiselog ph

Country Status (26)

Country Link
US (3) US11534433B2 (https=)
EP (3) EP4732902A2 (https=)
JP (1) JP7214714B2 (https=)
KR (1) KR102807716B1 (https=)
CN (2) CN111093655A (https=)
AU (2) AU2018309718B2 (https=)
BR (1) BR112020002290A2 (https=)
CA (1) CA3071940A1 (https=)
CY (1) CY1125690T1 (https=)
DK (1) DK3661503T3 (https=)
EA (1) EA202090445A1 (https=)
ES (1) ES2932658T3 (https=)
FI (1) FI3661503T3 (https=)
HR (1) HRP20221414T1 (https=)
HU (1) HUE060508T2 (https=)
LT (1) LT3661503T (https=)
MA (1) MA49751B1 (https=)
MD (1) MD3661503T2 (https=)
MX (1) MX2020001399A (https=)
PL (1) PL3661503T3 (https=)
PT (1) PT3661503T (https=)
RS (1) RS63746B1 (https=)
SI (1) SI3661503T1 (https=)
SM (1) SMT202200461T1 (https=)
TW (1) TWI805600B (https=)
WO (1) WO2019028034A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA55081A (fr) * 2019-02-27 2022-01-05 Scynexis Inc <smallcaps/>? ? ?pneumocystis? ? ? ? ?antifongiques triterpénoïdes pour le traitement ou la prévention de la pneumonie àspp
BR112021022876A2 (pt) * 2019-05-16 2022-04-12 Scynexis Inc Método para descolonizar candida auris de uma área anatômica de um sujeito
WO2022140646A1 (en) * 2020-12-26 2022-06-30 Mycovia Pharmaceuticals, Inc Dosing regimen for oteseconazole

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5756472A (en) 1996-01-31 1998-05-26 Merck & Co., Inc. Antifungal agent obtained from hormonema
DK2007396T3 (da) 2006-04-03 2013-03-18 Merck Sharp & Dohme Enfumafungin-derivat som antimykotika
RS53731B1 (sr) * 2008-08-12 2015-06-30 Scynexis, Inc. Antigljivični agensi
US8188085B2 (en) 2008-08-12 2012-05-29 Merck Sharp & Dohme Corp. Antifungal agents
LT3247711T (lt) 2015-01-19 2022-05-25 Scynexis, Inc. Naujos scy-078 druskos ir polimorfai
EP3609539A1 (en) * 2017-04-10 2020-02-19 Scynexis, Inc. Antifungal agents used in combination

Also Published As

Publication number Publication date
US20200390751A1 (en) 2020-12-17
CA3071940A1 (en) 2019-02-07
TW201919476A (zh) 2019-06-01
EP4169514B1 (en) 2026-01-28
CY1125690T1 (el) 2026-02-25
HUE060508T2 (hu) 2023-03-28
MD3661503T2 (ro) 2023-01-31
CN111093655A (zh) 2020-05-01
SI3661503T1 (sl) 2023-01-31
AU2018309718A1 (en) 2020-02-27
ES2932658T3 (es) 2023-01-23
SMT202200461T1 (it) 2023-01-13
EP4169514C0 (en) 2026-01-28
EP3661503B1 (en) 2022-09-07
EP3661503A1 (en) 2020-06-10
TWI805600B (zh) 2023-06-21
PL3661503T3 (pl) 2023-01-09
US11534433B2 (en) 2022-12-27
MA49751A (fr) 2020-06-10
MA49751B1 (fr) 2022-12-30
US20230364067A1 (en) 2023-11-16
CN118542868A (zh) 2024-08-27
LT3661503T (lt) 2022-12-12
EP4169514A1 (en) 2023-04-26
EP4732902A2 (en) 2026-04-29
WO2019028034A1 (en) 2019-02-07
RS63746B1 (sr) 2022-12-30
AU2018309718B2 (en) 2024-07-25
BR112020002290A2 (pt) 2020-09-08
MX2020001399A (es) 2020-08-06
US20260000656A1 (en) 2026-01-01
PT3661503T (pt) 2022-12-13
DK3661503T3 (da) 2022-12-12
JP2020529999A (ja) 2020-10-15
EA202090445A1 (ru) 2020-06-23
JP7214714B2 (ja) 2023-01-30
KR20200044823A (ko) 2020-04-29
FI3661503T3 (fi) 2022-12-15
AU2024227501A1 (en) 2024-11-07
KR102807716B1 (ko) 2025-05-13

Similar Documents

Publication Publication Date Title
HRP20231276T1 (hr) Inhibitor egfr-a za liječenje raka
HRP20221414T1 (hr) Antifungalni agensi sa pojačanom aktivnošću kod kiselog ph
PY2086023A (es) Derivados de pirazolilo útiles como agentes anticancerígenos
HRP20221086T1 (hr) Spojevi za liječenje karcinoma
FI3593817T3 (fi) Koostumus käytettäväksi likinäköisyyden ehkäisyssä tai vähentämisessä
Hu et al. Discovery of a series of dihydroquinoxalin-2 (1H)-ones as selective BET inhibitors from a dual PLK1-BRD4 inhibitor
IL305910B2 (en) Formulation of an oral dosage form of }]5–(3–chlorophenyl)–3–hydroxypyridine–2–carbonyl[amino{acetic acid
JP2014516942A5 (https=)
HRP20161674T1 (hr) 4-(8-METOKSI-1-((1-METOKSIPROPAN-2-IL)-2-(TETRAHIDRO-2H-PIRAN-4-IL)-1H-IMIDAZO[4,5-c]KINOLIN-7-IL)-3,5-DIMETILIZOKSAZOL I NJEGOVA UPOTREBA KAO INHIBITORA BROMODOMENE
AR075179A1 (es) Formulaciones galenicas de compuestos organicos que comprenden alisquireno
JP2018529742A5 (https=)
HRP20230935T1 (hr) Postupci za liječenje i profilaksu hiv-a i aids-a
JP2014511393A5 (https=)
Horiguchi et al. Blonanserin reverses the phencyclidine (PCP)-induced impairment in novel object recognition (NOR) in rats: role of indirect 5-HT1A partial agonism
HRP20251001T1 (hr) Inhibitor brutonove tirozin kinaze za upotrebu u liječenju kronične spontane urtikarije
FI3911304T3 (fi) Fosfodiesteraasin estäjiä sisältäviä muutettuja tablettiformulaatioita
ME02474B (me) Terapijski režimi
FI3897646T3 (fi) Masitentaani keuhkovaltimoverenpainetaudin hoitoon
IL270394B (en) Dementia therapeutic agent combining pyrazoloquinoline derivative and memantine
WO2007141530A2 (en) Treatment of excess sebum production
JP2020529999A5 (https=)
SK150797A3 (en) Antifungal composition
Yang et al. Discovery and identification of a novel PI3K inhibitor with enhanced CDK2 inhibition for the treatment of triple negative breast cancer
CA2660939A1 (en) Pharmaceutical compositions for the treatment of fungal infections
HRP20231448T1 (hr) Primjena delgocitiniba za liječenje kroničnog ekcema ruku